Nishath Altaf

Nishath Altaf

Auto-generated profile, based on publicly available information

Nishath Altaf

Royal Perth Hospital Perth WA Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in Anz Journal of Surgery
Verified
Journal Article
Open access
A(Australian And New Zealand Vascular Trial Network (Anzvtn)
Australian And New Zealand Vascular Trial Network (Anzvtn)
SASarah Aitken
Sarah Aitken
BABernard Allard
Bernard Allard
NANishath Altaf
Nishath Altaf
NANoel Atkinson
Noel Atkinson
JWJackie Wong
Jackie Wong
Background Frailty predicts adverse perioperative outcomes and increased mortality in patients having vascular surgery. Frailty assessment is a potential tool to inform resource allocation, and shared decision-making about vascular surgery in the resource constrained COVID-19 pandemic environment. This cohort study describes the prevalence of frailty in patients having vascular surgery and the association between frailty, mortality and perioperative outcomes. Methods The COVID-19 Vascular Service in Australia (COVER-AU) prospective cohort study evaluates 30-day and six-month outcomes for consecutive patients having vascular surgery in 11 Australian vascular units, March-July 2020. The primary outcome was mortality, with secondary outcomes procedure-related outcomes and hospital utilization. Frailty was assessed using the nine-point visual Clinical Frailty Score, scores of 5 or more considered frail. Results Of the 917 patients enrolled, 203 were frail (22.1%). The 30 day and 6 month mortality was 2.0% (n = 20) and 5.9% (n = 35) respectively with no significant difference between frail and non-frail patients (OR 1.68, 95%CI 0.79-3.54). However, frail patients stayed longer in hospital, had more perioperative complications, and were more likely to be readmitted or have a reoperation when compared to non-frail patients. At 6 months, frail patients had twice the odds of major amputation compared to non-frail patients, after adjustment (OR 2.01; 95% CI 1.17-3.78), driven by a high rate of amputation during the period of reduced surgical activity. Conclusion Our findings highlight that older, frail patients, experience potentially preventable adverse outcomes and there is a need for targeted interventions to optimize care, especially in times of healthcare stress.

9 March 2020 in Surgery Research and Practice
Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
RTRebekah L.W Tan
Rebekah L.W Tan
JFJoseph Faraj
Joseph Faraj
ADAli Daneshmand
Ali Daneshmand
OOOlufemi Oshin
Olufemi Oshin
SBSally A. Burrows
Sally A. Burrows
Background. Several studies have reported worse outcomes in women compared to men after endovascular aneurysm repair (EVAR). This study aimed to evaluate sex-specific short-term and 5-year outcomes after EVAR. Methods. A total of 409 consecutive patients underwent elective EVAR from 2004 to 2017 at two tertiary hospitals in Western Australia. Baseline, intraoperative, and postoperative variables were examined retrospectively according to sex. The primary outcome was 30-day mortality (death within 30 days after EVAR). Secondary outcomes were 30-day composite endpoint, length of stay after EVAR, 5-year survival, freedom from reintervention, residual aneurysm size after EVAR, and major adverse event rate at 5-year follow-up. Results. A cohort of 409 patients, comprising 57 women (14%) and 352 men (86%), was analysed. Female patients were older (median age, 76.8 versus 73.5 years, ). Male patients were more likely to be past smokers (40.9% versus 22.8%, ) and have a history of coronary artery bypass grafting (11.2% versus 3.5%, ) and malignancy (24.1% versus 10.5%, ). No difference in 30-day mortality or composite endpoints was demonstrated for female patients compared with male patients (3.5% versus 0.3%, and 31.6% versus 27.8%, , respectively). The Kaplan–Meier curves demonstrated similar 5-year mortality outcomes amongst male and female patients (). Long-term survival analysis adjusting for covariates demonstrated no significant difference in long-term mortality, composite endpoints, and reintervention rate between sexes. Conclusion. This study found no significant differences in 30-day and 5-year outcomes between female and male patients treated with EVAR, implying that EVAR remains a safe treatment choice for female patients.